Insights
Insights

Quality assessment in single-arm trials: insights for systematic reviews
Written by Hannah Shapiro
Quality assessment in single-arm trials
Quality assessment is a vital ...

A ‘NICE’ Innovation: The Proportionate Approach
Written by Kiera Lander, Assistant Project Manager
The National Institute for Health and Care ...

Out of the frying pan and into the fire: Moving to a market access consultancy company
Written by Brian O'Toole, HTA Writing Lead
Last year I changed jobs.
It was a major life decision ...

AI-enabled triage in the NHS: an economic analysis
Written by Mark Pennington, Consultant Health Economist
With the UK’s National Health Service (NHS) ...

Modelling requirements for HTA in Europe’s big 5 economies
Written by Oliver Burn, Consultant Health Economist, and Margaret Petrou, Consultant Health Economist
Adapting a ...

Advances in artificial intelligence: ChatGPT and the implications for medical writing
Written by Dom Partridge, Medical Writer
As artificial intelligence (AI) technology continues to advance, natural ...

Obtaining a NICE recommendation for your medical device: a view from the external assessors
Written by Mark Pennington, Consultant Health Economist
A National Institute for Health and Care Excellence ...

10 steps for a successful global economic model
Written by Beth Hancock, Senior Consultant Health Economist
Pharmaceutical companies often develop global ...

Conceptual modelling and NICE requirements: a significant change or hill of beans?
Written by Alec Miners, Head of Health Economics
The National Institute for Health and Care Excellence’s ...

British Heart Week 2022
As we approach the end of British Heart Week, we reflect on some of the key stats around heart conditions in the ...

Patient Participation Groups: A voice for patients for 50 years
Written by Dom Partridge, Medical Writer
6th to 13th June 2022 is Patient Participation Group (PPG) Awareness ...

The Innovative Medicines Fund is now available to fast-track non-cancer medicines recommended with managed access
The Innovative Medicines Fund (IMF) launched this month (June 2022) to support faster access to non-cancer drugs. This process involves NHS England and the National Institute for Health and Care Excellence (NICE) working in partnership with pharmaceutical companies to respond to the long-standing challenge of evaluating medicines and addressing the uncertainty around their effectiveness.
No results found.